MX2017016835A - Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. - Google Patents
Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.Info
- Publication number
- MX2017016835A MX2017016835A MX2017016835A MX2017016835A MX2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- individual
- treating autoimmune
- alloimmune
- present disclosure
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 230000001363 autoimmune Effects 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona métodos para tratar un trastorno aloinmunitario o autoinmunitario en un individuo; en donde los métodos implican administrar al individuo una cantidad eficaz de un anticuerpo específico para un componente del complemento Cls. La presente descripción proporciona un método para monitorear la eficacia de un método de tratamiento de un sujeto; en donde el método implica detectar el nivel de autoanticuerpo o aloanticuerpo en una muestra biológica obtenida del individuo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562185362P | 2015-06-26 | 2015-06-26 | |
PCT/US2016/039087 WO2016210172A1 (en) | 2015-06-26 | 2016-06-23 | Methods of treating autoimmune and alloimmune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016835A true MX2017016835A (es) | 2018-08-01 |
Family
ID=57585852
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016835A MX2017016835A (es) | 2015-06-26 | 2016-06-23 | Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. |
MX2023002021A MX2023002021A (es) | 2015-06-26 | 2017-12-19 | Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002021A MX2023002021A (es) | 2015-06-26 | 2017-12-19 | Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20180169240A1 (es) |
EP (1) | EP3313417A4 (es) |
JP (1) | JP6963509B2 (es) |
KR (1) | KR20180020296A (es) |
CN (1) | CN108348600A (es) |
AU (2) | AU2016282782A1 (es) |
BR (1) | BR112017027578A2 (es) |
CA (1) | CA2990662A1 (es) |
EA (1) | EA038567B1 (es) |
HK (1) | HK1254030A1 (es) |
IL (1) | IL256424B1 (es) |
MX (2) | MX2017016835A (es) |
WO (1) | WO2016210172A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2889170C (en) | 2012-10-25 | 2021-09-07 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
CN116063483A (zh) | 2012-11-02 | 2023-05-05 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
ES2938359T3 (es) | 2015-04-06 | 2023-04-10 | Bioverativ Usa Inc | Anticuerpos humanizados anti-C1s y métodos de uso de los mismos |
CN109069606B (zh) * | 2016-04-29 | 2022-07-01 | 辉瑞大药厂 | 干扰素β抗体及其用途 |
SG11202011647SA (en) * | 2019-10-16 | 2021-05-28 | Chugai Pharmaceutical Co Ltd | An antibody, a pharmaceutical composition, and a method |
WO2023287573A2 (en) | 2021-07-13 | 2023-01-19 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6929100A (en) * | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
NZ538384A (en) * | 2002-09-06 | 2009-04-30 | Alexion Pharma Inc | Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors |
US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
CA2720682A1 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
RU2012102021A (ru) * | 2009-06-23 | 2013-07-27 | Алексион Фармасьютикалз, Инк. | Биспецифические антитела, которые связываются с белками комплемента |
CA2889170C (en) * | 2012-10-25 | 2021-09-07 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
CN116063483A (zh) * | 2012-11-02 | 2023-05-05 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
-
2016
- 2016-06-23 CA CA2990662A patent/CA2990662A1/en active Pending
- 2016-06-23 KR KR1020187002518A patent/KR20180020296A/ko not_active Application Discontinuation
- 2016-06-23 EA EA201890106A patent/EA038567B1/ru unknown
- 2016-06-23 IL IL256424A patent/IL256424B1/en unknown
- 2016-06-23 AU AU2016282782A patent/AU2016282782A1/en not_active Abandoned
- 2016-06-23 US US15/739,622 patent/US20180169240A1/en not_active Abandoned
- 2016-06-23 CN CN201680044603.9A patent/CN108348600A/zh active Pending
- 2016-06-23 JP JP2017567174A patent/JP6963509B2/ja active Active
- 2016-06-23 BR BR112017027578A patent/BR112017027578A2/pt active Search and Examination
- 2016-06-23 MX MX2017016835A patent/MX2017016835A/es unknown
- 2016-06-23 WO PCT/US2016/039087 patent/WO2016210172A1/en active Application Filing
- 2016-06-23 EP EP16815332.8A patent/EP3313417A4/en active Pending
-
2017
- 2017-12-19 MX MX2023002021A patent/MX2023002021A/es unknown
-
2018
- 2018-10-10 HK HK18112887.1A patent/HK1254030A1/zh unknown
-
2021
- 2021-09-08 US US17/469,625 patent/US20220249664A1/en active Pending
-
2022
- 2022-08-12 AU AU2022215307A patent/AU2022215307A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180169240A1 (en) | 2018-06-21 |
US20220249664A1 (en) | 2022-08-11 |
KR20180020296A (ko) | 2018-02-27 |
IL256424A (en) | 2018-02-28 |
JP2018526330A (ja) | 2018-09-13 |
EP3313417A1 (en) | 2018-05-02 |
BR112017027578A2 (pt) | 2018-08-28 |
IL256424B1 (en) | 2024-05-01 |
EA201890106A1 (ru) | 2018-05-31 |
CN108348600A (zh) | 2018-07-31 |
HK1254030A1 (zh) | 2019-07-12 |
EA038567B1 (ru) | 2021-09-15 |
CA2990662A1 (en) | 2016-12-29 |
MX2023002021A (es) | 2023-03-15 |
EP3313417A4 (en) | 2019-06-12 |
WO2016210172A1 (en) | 2016-12-29 |
JP6963509B2 (ja) | 2021-11-10 |
AU2022215307A1 (en) | 2022-09-08 |
AU2016282782A1 (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002021A (es) | Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune. | |
MX2017005751A (es) | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. | |
MX364886B (es) | Lente oftálmica con sistema microfluídico. | |
PH12017502222A1 (en) | Lag-3-binding molecules and methods of use thereof | |
MX2017015758A (es) | Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas. | |
EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
MX2017001138A (es) | Metodo. | |
WO2014169226A3 (en) | Methods of diagnosing and treating chronic pain | |
ZA201800498B (en) | Anti¿pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis | |
EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
MX2015017807A (es) | Sistema cerrado integrado de extraccion de linea intravenosa. | |
MX2015009392A (es) | Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias. | |
BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
MX2019011252A (es) | Anticuerpos anti-c5a y usos de los mismos. | |
EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
MX2018012939A (es) | Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas. | |
NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
MX2016006584A (es) | Métodos y composiciones para tratar los depósitos de amiloide. | |
FR3029016B1 (fr) | Procede d'enrichissement d'une electrode d'un dispositif electrochimique en espece ionique. | |
MX2017016337A (es) | Tratamiento de carcinoma de linea media nut. | |
MX2016012278A (es) | Deteccion temprana de preeclampsia. | |
WO2014138176A3 (en) | Apparatus and method for analyzing blood clotting |